AR119331A1 - Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos - Google Patents

Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos

Info

Publication number
AR119331A1
AR119331A1 ARP200101868A ARP200101868A AR119331A1 AR 119331 A1 AR119331 A1 AR 119331A1 AR P200101868 A ARP200101868 A AR P200101868A AR P200101868 A ARP200101868 A AR P200101868A AR 119331 A1 AR119331 A1 AR 119331A1
Authority
AR
Argentina
Prior art keywords
psma
group
ligands
specific membrane
membrane antigen
Prior art date
Application number
ARP200101868A
Other languages
English (en)
Inventor
Maurizio F Mariani
Lorenza Fugazza
Daniela Chicco
Martin Gilbert Pomper
Sangeeta Ray
Original Assignee
Advanced Accelerator Applications Italy Srl
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Italy Srl, Univ Johns Hopkins filed Critical Advanced Accelerator Applications Italy Srl
Publication of AR119331A1 publication Critical patent/AR119331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ligandos para antígeno de membrana específico de próstata (PSMA), composición farmacéutica que los comprende y el uso de los mismos para el tratamiento del cáncer de próstata, para métodos de obtención de imágenes y para diagnóstico o detección de células de cáncer, tumores o células que expresan PSMA. Reivindicación 1: Un compuesto de la fórmula (1) en donde: Z es tetrazol o COOQ, preferiblemente Z es COOQ; Q es H o un grupo protector, preferiblemente Q es H; m es un número entero seleccionado del grupo que consiste en 1, 2, 3, 4 y 5, preferiblemente m es 4; R está seleccionado del grupo que consiste en arilo sustituido, piridina sustituida e isoquinolina no sustituida; W está seleccionado del grupo que consiste en -NR²-(C=O), -NR²-(C=S), -(C=O)-NR²-, y -(C=S)-NR²-, preferiblemente, W es -(C=O)-NR²-; R² es H o C₁₋₄ alquilo, preferiblemente R² es H; Ch es un agente quelante que opcionalmente comprende un metal o un radiometal; y sales farmacéuticamente aceptables del mismo.
ARP200101868A 2019-07-02 2020-07-01 Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos AR119331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19184015 2019-07-02

Publications (1)

Publication Number Publication Date
AR119331A1 true AR119331A1 (es) 2021-12-09

Family

ID=67145647

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101868A AR119331A1 (es) 2019-07-02 2020-07-01 Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos

Country Status (15)

Country Link
US (1) US20230226227A1 (es)
EP (1) EP3993837A1 (es)
JP (1) JP2022538478A (es)
KR (1) KR20220044496A (es)
CN (1) CN114341118A (es)
AR (1) AR119331A1 (es)
AU (2) AU2020299974A1 (es)
BR (1) BR112021026812A2 (es)
CA (1) CA3144557A1 (es)
CL (1) CL2021003525A1 (es)
CO (1) CO2021017708A2 (es)
IL (1) IL289039A (es)
MX (1) MX2022000136A (es)
TW (1) TW202114742A (es)
WO (1) WO2021001360A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523235A (ja) * 2020-04-29 2023-06-02 ノバルティス アーゲー Ｐｓｍａ結合リガンドを放射標識するための方法及びそれらのキット

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254102A1 (en) 2000-07-11 2004-12-16 Yuji Yoshiko Remedies for bone diseases
EP4374924A2 (en) * 2013-10-18 2024-05-29 Novartis AG Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2017165473A1 (en) 2016-03-22 2017-09-28 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
AU2019217838C1 (en) * 2018-02-06 2024-05-02 Duke University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
US20210338846A1 (en) * 2018-07-30 2021-11-04 The Johns Hopkins University Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
IL289039A (en) 2022-02-01
CL2021003525A1 (es) 2022-10-21
AU2024200850A1 (en) 2024-02-29
AU2020299974A1 (en) 2022-01-27
MX2022000136A (es) 2022-04-27
KR20220044496A (ko) 2022-04-08
JP2022538478A (ja) 2022-09-02
BR112021026812A2 (pt) 2022-02-22
EP3993837A1 (en) 2022-05-11
TW202114742A (zh) 2021-04-16
US20230226227A1 (en) 2023-07-20
WO2021001360A1 (en) 2021-01-07
CA3144557A1 (en) 2021-01-07
CO2021017708A2 (es) 2022-05-20
CN114341118A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
AR115326A1 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
AR110056A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
AR109349A1 (es) Compuestos y usos
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR107154A1 (es) Estimuladores de guanilato ciclasa soluble
AR117544A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
AR115296A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
EP3533473A3 (en) Compounds for positron emission tomography
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
AR110790A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR117398A1 (es) Inhibidores de la señalización mediada por tirosina cinasa 2
AR119331A1 (es) Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos
AR115007A1 (es) Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método
AR040078A1 (es) Diaminotiazoles
JP2019513829A5 (es)
CY1123927T1 (el) Παραγωγο 5-μεθυλ-6-φαινυλ-4,5-διυδρο-2η-πυριδαζιν-3-ονης για τη θεραπεια ογκων του εγκεφαλου
WO2020028324A1 (en) Long-circulating psma-targeted phototheranostic agent
ATE386029T1 (de) Urokinase-inhibitoren
DK1305041T3 (da) Lægemiddel til immunterapi af maligne tumorer